Travel vaccines market seen topping $6.46 billion by 2030

The travel vaccines market is projected to grow quickly through 2030 as international travel rebounds and more countries require pre-travel immunization. North America is expected to lead the market, while hepatitis A remains the largest disease segment.

Why it matters: - More international travel is increasing demand for vaccines that protect against region-specific diseases. - The market is projected to exceed $6 billion by 2030 and reach $6.46 billion, making travel vaccines a small but growing slice of the broader preventive vaccines sector. - Rising vaccination requirements, outbreak awareness and travel health rules are shaping how travelers prepare for trips abroad.

What happened: - The Business Research Company released The Travel Vaccines Global Market Report 2026, covering market size, trends and forecasts through 2035. - The report projects the travel vaccines market will grow at a 7% compound annual growth rate through 2030. - North America is forecast to be the largest regional market in 2030, at $2.1 billion, up from $1.5 billion in 2025. - The United States is expected to be the largest country market, reaching $1.9 billion in 2030 from $1.4 billion in 2025.

The details: - Hepatitis A is expected to be the biggest disease segment, representing 25% of the market and worth $2 billion in 2030. - Other disease categories in the market include DPT, yellow fever, typhoid, hepatitis B, measles and mumps, rabies, meningococcal and others. - The market is also segmented by composition into mono vaccines and combination vaccines. - Booking channels include online and in-person booking. - Application segments include domestic travel and outbound travel. - Between 2025 and 2030, hepatitis A vaccines are expected to add $1 billion in value. - DPT vaccines are projected to add $0.3 billion. - Yellow fever, typhoid and hepatitis B vaccines are each projected to add $0.2 billion. - Measles and mumps vaccines, rabies vaccines and meningococcal vaccines are each projected to add $0.1 billion. - Other disease categories are projected to add $0.2 billion. - Collectively, disease-specific travel vaccine categories are projected to add more than $2.4 billion by 2030.

Between the lines: - The market’s growth is tied to outbound tourism, business travel, education travel and adventure travel. - Demand is also rising because travelers are moving into destinations with higher risks of yellow fever, hepatitis, typhoid and rabies. - The report points to airport clinics, retail vaccination outlets, private travel clinics, pharmacy-based services, employer-supported programs and telehealth as expanding access points. - The market remains moderately fragmented, with the top 10 companies accounting for 22% of revenue in 2025. - Sanofi S.A. led the market in 2025 with a 5% global share. - The report lists major players including GSK, Pfizer, Merck, Takeda, Bavarian Nordic, CSL, Serum Institute of India, Valneva, Bharat Biotech and others.

What's next: - The report expects continued growth in travel vaccine demand as global travel recovery, public health campaigns and vaccination compliance trends continue. - Companies are focusing on vaccine research and development, new vaccine platforms, cold-chain expansion and travel vaccine decision-support tools. - In January 2024, Indian Immunologicals Ltd. launched Havisure, described as India’s first domestically developed hepatitis A vaccine for travelers and at-risk groups. - Market competition is likely to stay focused on regulatory approvals, global manufacturing capacity and geographic expansion.

The bottom line: - Travel vaccines are becoming a bigger global health business as more travelers seek protection before crossing borders, and hepatitis A remains the clearest growth driver.